Covered recipient · General Payments record
DIANE RYDER COUNCE
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$85,668.96
283 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $43,622.00 | 16 |
| Consulting Fee | $24,966.50 | 10 |
| Honoraria | $6,900.50 | 4 |
| Food and Beverage | $5,198.48 | 230 |
| Travel and Lodging | $4,882.48 | 22 |
| Education | $99.00 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $70,433.41 | 110 |
| Axsome Therapeutics, Inc. | $7,211.42 | 23 |
| Neurelis, Inc. | $5,145.96 | 15 |
| UCB, Inc. | $585.45 | 39 |
| PFIZER INC. | $299.85 | 14 |
| Janssen Biotech, Inc. | $208.52 | 5 |
| Merz Pharmaceuticals, LLC | $157.65 | 6 |
| Lundbeck LLC | $154.24 | 6 |
| AstraZeneca Pharmaceuticals LP | $139.41 | 8 |
| SK Life Science, Inc. | $138.36 | 5 |
| Aucta Pharmaceuticals, Inc. | $127.92 | 6 |
| Biogen, Inc. | $118.43 | 5 |
| Eisai Inc. | $117.35 | 4 |
| ARGENX US, INC. | $89.46 | 5 |
| JAZZ PHARMACEUTICALS INC. | $78.68 | 3 |
| ACADIA Pharmaceuticals Inc | $73.21 | 3 |
| Amgen Inc. | $63.54 | 3 |
| CATALYST PHARMACEUTICALS, INC. | $62.40 | 3 |
| AERIN MEDICAL INC. | $62.00 | 1 |
| Forte Bio-Pharma LLC | $61.43 | 3 |
| Lilly USA, LLC | $56.03 | 3 |
| Ipsen Biopharmaceuticals, Inc | $40.59 | 2 |
| Teva Pharmaceuticals USA, Inc. | $38.83 | 2 |
| Impel Pharmaceuticals LLC | $36.49 | 2 |
| EMD Serono, Inc. | $34.10 | 1 |
| Alexion Pharmaceuticals, Inc. | $27.10 | 1 |
| Monteris Medical Corporation | $23.55 | 1 |
| Hyperfine Operations, Inc. | $22.74 | 1 |
| SCILEX PHARMACEUTICALS INC. | $21.47 | 1 |
| KYOWA KIRIN, INC. | $20.16 | 1 |
| Kedrion Biopharma, Inc. | $19.21 | 1 |
Page 2 of 6; records 51–100 of 283 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DIANE RYDER COUNCE
NPI 1417989740 · CMS profile ID 290771
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
BIRMINGHAM, AL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 6; records 51–100 of 283 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1417989740?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DIANE RYDER COUNCE, NPI 1417989740, CMS profile ID 290771. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 283 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417989740?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). DIANE RYDER COUNCE, NPI 1417989740, CMS profile ID 290771. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 283 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417989740?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- DIANE RYDER COUNCE, NPI 1417989740, CMS profile ID 290771, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 283 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1417989740?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
283 matching records · $85,668.96 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 283.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $487.50 | 10/09/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201700133 | CMS |
| CATALYST PHARMACEUTICALS, INC. | $21.57 | 10/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1253219337 | CMS |
| Axsome Therapeutics, Inc. | $2.77 | 10/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235569551 | CMS |
| Axsome Therapeutics, Inc. | $1,150.00 | 10/08/2025 | Honoraria | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235754333 | CMS |
| Janssen Biotech, Inc. | $29.75 | 10/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174340087 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.79 | 10/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207016190 | CMS |
| Amgen Inc. | $17.70 | 10/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228258054 | CMS |
| Biogen, Inc. | $24.65 | 10/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1208414948 | CMS |
| UCB, Inc. | $3.76 | 10/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224627345 | CMS |
| UCB, Inc. | $24.86 | 10/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224627347 | CMS |
| Alexion Pharmaceuticals, Inc. | $27.10 | 10/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202921402 | CMS |
| Axsome Therapeutics, Inc. | $1,725.00 | 09/30/2025 | Honoraria | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235754475 | CMS |
| Axsome Therapeutics, Inc. | $14.70 | 09/30/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235812418 | CMS |
| Axsome Therapeutics, Inc. | $4.00 | 09/30/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235813154 | CMS |
| Neurelis, Inc. | $23.57 | 09/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1219188113 | CMS |
| ABBVIE INC. | $6.53 | 09/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201700131 | CMS |
| ABBVIE INC. | $10.76 | 09/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201700127 | CMS |
| ABBVIE INC. | $1.87 | 09/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201700129 | CMS |
| Teva Pharmaceuticals USA, Inc. | $18.45 | 09/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1247283330 | CMS |
| Merz Pharmaceuticals, LLC | $27.30 | 09/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1232559157 | CMS |
| Eisai Inc. | $27.90 | 09/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1244476644 | CMS |
| PFIZER INC. | $16.94 | 09/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229147382 | CMS |
| SK Life Science, Inc. | $22.75 | 09/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1252276281 | CMS |
| ACADIA Pharmaceuticals Inc | $23.90 | 09/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1247770325 | CMS |
| UCB, Inc. | $6.51 | 09/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224627339 | CMS |
| UCB, Inc. | $9.55 | 09/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224627341 | CMS |
| UCB, Inc. | $11.18 | 09/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224627343 | CMS |
| ABBVIE INC. | $5.08 | 09/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201700125 | CMS |
| UCB, Inc. | $0.67 | 09/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224773387 | CMS |
| UCB, Inc. | $8.39 | 09/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224773389 | CMS |
| UCB, Inc. | $22.38 | 09/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224773391 | CMS |
| Amgen Inc. | $22.00 | 09/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228258056 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.96 | 09/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206156062 | CMS |
| UCB, Inc. | $2.71 | 09/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224773381 | CMS |
| UCB, Inc. | $7.19 | 09/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224773383 | CMS |
| UCB, Inc. | $15.42 | 09/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224773385 | CMS |
| Monteris Medical Corporation | $23.55 | 09/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1251570575 | CMS |
| ABBVIE INC. | $20.91 | 08/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201700123 | CMS |
| Merz Pharmaceuticals, LLC | $23.22 | 08/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1232559155 | CMS |
| ABBVIE INC. | $33.83 | 08/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201700121 | CMS |
| ABBVIE INC. | $1,787.50 | 08/21/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201700115 | CMS |
| ABBVIE INC. | $67.74 | 08/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201700117 | CMS |
| ABBVIE INC. | $34.00 | 08/21/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201700119 | CMS |
| ARGENX US, INC. | $15.95 | 08/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1240435707 | CMS |
| Axsome Therapeutics, Inc. | $7.95 | 08/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235507560 | CMS |
| Forte Bio-Pharma LLC | $19.19 | 08/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1251430059 | CMS |
| Neurelis, Inc. | $832.00 | 08/21/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1219188111 | CMS |
| ABBVIE INC. | $1,462.50 | 08/20/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201700111 | CMS |
| ABBVIE INC. | $4,550.00 | 08/20/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201700113 | CMS |
| Axsome Therapeutics, Inc. | $33.66 | 08/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235507513 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $51,974.84 | 28 |
| PY2024 | Principal investigator | $226,963.03 | 60 |
| PY2023 | Recipient | $11,597.38 | 5 |
| PY2023 | Principal investigator | $107,834.07 | 41 |
| PY2022 | Principal investigator | $95,889.70 | 33 |
| PY2021 | Recipient | $7,000.06 | 2 |
| PY2021 | Principal investigator | $18,128.90 | 8 |
| PY2020 | Principal investigator | $7,100.00 | 1 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
28 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $1,545.00 | 12/31/2025 | Non-covered Recipient Entity ACHIEVE CLINICAL RESEARCH LLC | A Phase 3 Multicenter 24-Week Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Atogepant When Added to OnabotulinumtoxinA (BOTOX) for the Preventive Treatment of Chronic Migraine | No dispute reported | 06/30/2026 | 1202534935 |
| Principal investigator 1 | ABBVIE INC. | $1,082.56 | 12/31/2025 | Non-covered Recipient Entity ACHIEVE CLINICAL RESEARCH LLC | A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Upper Limb Essential Tremor | No dispute reported | 06/30/2026 | 1202534937 |
| Principal investigator 1 | H. Lundbeck A S | $3,990.00 | 07/10/2025 | Non-covered Recipient Entity ACHIEVE CLINICAL RESEARCH LLC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251772012 |
| Principal investigator 1 | ABBVIE INC. | $453.72 | 07/02/2025 | Non-covered Recipient Entity ACHIEVE CLINICAL RESEARCH LLC | Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine | No dispute reported | 06/30/2026 | 1202496113 |
| Principal investigator 1 | H. Lundbeck A S | $2,407.00 | 06/05/2025 | Non-covered Recipient Entity ACHIEVE CLINICAL RESEARCH LLC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251770767 |
| Principal investigator 1 | H. Lundbeck A S | $4,228.64 | 05/15/2025 | Non-covered Recipient Entity ACHIEVE CLINICAL RESEARCH LLC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251770309 |
| Principal investigator 1 | ABBVIE INC. | $465.75 | 05/08/2025 | Non-covered Recipient Entity ACHIEVE CLINICAL RESEARCH LLC | Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | No dispute reported | 06/30/2026 | 1202484207 |
| Principal investigator 1 | ABBVIE INC. | $67.50 | 05/08/2025 | Non-covered Recipient Entity ACHIEVE CLINICAL RESEARCH LLC | Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | No dispute reported | 06/30/2026 | 1202484209 |
| Principal investigator 1 | ABBVIE INC. | $2,493.45 | 05/08/2025 | Non-covered Recipient Entity ACHIEVE CLINICAL RESEARCH LLC | Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | No dispute reported | 06/30/2026 | 1202484211 |
| Principal investigator 1 | ABBVIE INC. | $310.50 | 05/08/2025 | Non-covered Recipient Entity ACHIEVE CLINICAL RESEARCH LLC | Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | No dispute reported | 06/30/2026 | 1202484213 |
| Principal investigator 1 | ABBVIE INC. | $274.20 | 05/08/2025 | Non-covered Recipient Entity ACHIEVE CLINICAL RESEARCH LLC | Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | No dispute reported | 06/30/2026 | 1202484219 |
| Principal investigator 1 | ABBVIE INC. | $621.00 | 05/08/2025 | Non-covered Recipient Entity ACHIEVE CLINICAL RESEARCH LLC | Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | No dispute reported | 06/30/2026 | 1202484221 |
| Principal investigator 1 | ABBVIE INC. | $155.25 | 05/08/2025 | Non-covered Recipient Entity ACHIEVE CLINICAL RESEARCH LLC | Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | No dispute reported | 06/30/2026 | 1202484223 |
| Principal investigator 1 | ABBVIE INC. | $135.00 | 05/08/2025 | Non-covered Recipient Entity ACHIEVE CLINICAL RESEARCH LLC | Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | No dispute reported | 06/30/2026 | 1202484225 |
| Principal investigator 1 | ABBVIE INC. | $2,660.00 | 05/07/2025 | Non-covered Recipient Entity ACHIEVE CLINICAL RESEARCH LLC | Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine (CORNERSTONE) | No dispute reported | 06/30/2026 | 1202482407 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 05/06/2025 | Non-covered Recipient Entity ACHIEVE CLINICAL RESEARCH LLC | Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | No dispute reported | 06/30/2026 | 1202481189 |
| Principal investigator 1 | H. Lundbeck A S | $3,713.34 | 04/28/2025 | Non-covered Recipient Entity ACHIEVE CLINICAL RESEARCH LLC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251769886 |
| Principal investigator 1 | PFIZER INC. | $999.23 | 04/24/2025 | Non-covered Recipient Entity Achieve Clinical Research LLC | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228777565 |
| Principal investigator 1 | H. Lundbeck A S | $3,990.00 | 04/22/2025 | Non-covered Recipient Entity ACHIEVE CLINICAL RESEARCH LLC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251769780 |
| Principal investigator 1 | Sage Therapeutics, LLC | $1,670.50 | 04/17/2025 | Non-covered Recipient Entity ACHIEVE CLINICAL RESEARCH LLC | Study to Evaluate SAGE-324 in Participants With Essential Tremors | No dispute reported | 06/30/2026 | 1206580577 |
| Principal investigator 1 | H. Lundbeck A S | $3,990.00 | 03/19/2025 | Non-covered Recipient Entity ACHIEVE CLINICAL RESEARCH LLC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251768853 |
| Principal investigator 1 | ABBVIE INC. | $2,333.45 | 03/06/2025 | Non-covered Recipient Entity ACHIEVE CLINICAL RESEARCH LLC | M21-471 - Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | No dispute reported | 06/30/2026 | 1202457860 |
| Principal investigator 1 | PFIZER INC. | $1,460.50 | 02/13/2025 | Non-covered Recipient Entity Achieve Clinical Research LLC | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228765890 |
| Principal investigator 1 | ABBVIE INC. | $155.25 | 02/06/2025 | Non-covered Recipient Entity ACHIEVE CLINICAL RESEARCH LLC | M21-471 - Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | No dispute reported | 06/30/2026 | 1202449097 |
| Principal investigator 1 | Sage Therapeutics, LLC | $3,000.00 | 02/06/2025 | Non-covered Recipient Entity ACHIEVE CLINICAL RESEARCH LLC | A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor | No dispute reported | 06/30/2026 | 1206580572 |
| Principal investigator 1 | H. Lundbeck A S | $3,990.00 | 02/05/2025 | Non-covered Recipient Entity ACHIEVE CLINICAL RESEARCH LLC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251766959 |
| Principal investigator 1 | H. Lundbeck A S | $1,400.00 | 01/07/2025 | Non-covered Recipient Entity ACHIEVE CLINICAL RESEARCH LLC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251766209 |
| Principal investigator 1 | ABBVIE INC. | $3,633.00 | 01/02/2025 | Non-covered Recipient Entity ACHIEVE CLINICAL RESEARCH LLC | M21-471 - Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | No dispute reported | 06/30/2026 | 1202435464 |